CBSC (Cardiac Biotech Solutions) Selling, General, & Admin. Expense: $0.56 Mil (TTM As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cardiac Biotech Solutions Selling, General, & Admin. Expense?

Cardiac Biotech Solutions CBSC Selling, General, & Admin. Expense is $0.56 Mil as of Jun. 2025.

Selling, general, & admin. expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. Cardiac Biotech Solutions's selling, general, & admin. expense for the three months ended in Jun. 2025 was $0.21 Mil. Its selling, general, & admin. expense for the trailing twelve months (TTM) ended in Jun. 2025 was $0.56 Mil.


Cardiac Biotech Solutions  (OTCPK:CBSC) Selling, General, & Admin. Expense Explanation

An efficient operation keeps SGA costs low and thus has higher profit margin. The percentage of SGA relative to total revenue is an indication of how efficiently the company operates. Compare this percentage among the companies in the same industry is a good way of finding more efficient operations. A comparison of the SGA cost relative to the revenue with the historical value can also be an indication of how efficient the company has become.

Warren Buffett likes companies with consistent SGA as the percentage of gross profit.

Companies with no durable competitive advantage show wild variation in SG&A as % of Gross Profit.

If SGA is less than 30% of Gross Profit, it is fantastic. If SGA is nearing 100%, it is is in highly competitive industry.


Cardiac Biotech Solutions Selling, General, & Admin. Expense Related Terms


Cardiac Biotech Solutions Selling, General, & Admin. Expense Historical Data

* Premium members only.

The historical data trend for Cardiac Biotech Solutions's Selling, General, & Admin. Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiac Biotech Solutions Selling, General, & Admin. Expense Chart

Cardiac Biotech Solutions Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25
Selling, General, & Admin. Expense
2.96 1.80 1.66 1.31 1.20

Cardiac Biotech Solutions Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Mar25 Jun25
Selling, General, & Admin. Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.08 0.25 0.35 0.00 0.21

CBSC vs LUCY, NXGL, MHUAF: Selling, General, & Admin. Expense Comparison

For the Medical Instruments & Supplies subindustry, Cardiac Biotech Solutions's Selling, General, & Admin. Expense, along with its competitors' market caps and Selling, General, & Admin. Expense data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cardiac Biotech Solutions Selling, General, & Admin. Expense vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cardiac Biotech Solutions's Selling, General, & Admin. Expense distribution charts can be found below:

* The bar in red indicates where Cardiac Biotech Solutions's Selling, General, & Admin. Expense falls into.



Cardiac Biotech Solutions Selling, General, & Admin. Expense Calculation

Selling, General, & Admin. Expense (SGA) includes the direct and indirect costs and all general and administrative expenses of a company. For instance, personnel cost, advertising, rent, communication costs are all part of SGA.

Selling, General, & Admin. Expense for the trailing twelve months (TTM) ended in Jun. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.56 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Selling, General, & Admin. Expense of $0.56 Mil mean?
Cardiac Biotech Solutions (CBSC) has a Selling, General, & Admin. Expense of $0.56 Mil as of Jun. 2025. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Cardiac Biotech Solutions and its competitors.
Is Cardiac Biotech Solutions' Selling, General, & Admin. Expense too high?
Cardiac Biotech Solutions' current Selling, General, & Admin. Expense is $0.56 Mil.
How does Cardiac Biotech Solutions' Selling, General, & Admin. Expense compare to LUCY and NXGL?
Cardiac Biotech Solutions' Selling, General, & Admin. Expense of $0.56 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Selling, General, & Admin. Expense for a Medical Devices & Instruments company?
A good Selling, General, & Admin. Expense depends on the Medical Devices & Instruments industry context. However, Selling, General, & Admin. Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Selling, General, & Admin. Expense mean?
A high Selling, General, & Admin. Expense can signal that a stock is expensive relative to its fundamentals. Selling, general and admin expense is the total cost for direct, indirect, general and administrative activities. View historical data on Cardiac Biotech Solutions and its competitors. Cardiac Biotech Solutions's current Selling, General, & Admin. Expense is $0.56 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiac Biotech Solutions stock overvalued right now?
Cardiac Biotech Solutions (CBSC) has a current Selling, General, & Admin. Expense of $0.56 Mil. The current Selling, General, & Admin. Expense is $0.56 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Selling, General, & Admin. Expense calculated?
Selling, General, & Admin. Expense is calculated from a company's financial statements. For Cardiac Biotech Solutions (CBSC), the current Selling, General, & Admin. Expense is $0.56 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiac Biotech Solutions Business Description

Address 10845 Griffith Peak Drive, Suite 200, Las Vegas, NV, USA, 89135
Cardiac Biotech Solutions Inc, through its U.S. and international subsidiaries, provides products and services in the ambulatory non-invasive cardiac monitoring space. The FDA and CE cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms, provide improved compliance for patients at risk of abnormal heart rhythms as well as more accurate information for physicians.